Cambridge Healthtech Institute’s Second Annual

Circulating Cell-Free DNA

Pushing the Limits of Early Detection

February 19-20, 2015 | The InterContinental San Francisco | San Francisco, CA
Part of the 22nd International Molecular Medicine Tri-Conference

 

About this Conference:

Circulating nucleic acids are an important emerging biomarker in cancer diagnostics as well as a non-invasive diagnostic solution for a wide range of clinical disorders. Cambridge Healthtech Institute's Second Annual Circulating Cell-Free DNA will cover clinical, technical, and biological aspects of both cfDNA and cfRNA. In addition to exploring applications in cancer, this event will assess existing detection technologies and showcase novel approaches for rare event and minimal residual disease detection.


CIRCULATING TUMOR DNA

KEYNOTE PRESENTATION
Detection of Circulating Tumor DNA in Early and Late Stage Human Malignancies

Chetan Bettegowda, M.D., Ph.D., Assistant Professor, Neurosurgery & Oncology, Johns Hopkins University School of Medicine

Tracking Changes in Circulating Tumor DNA in Patients with Non-Small Cell Lung Cancer

Abhijit A. Patel, M.D., Ph.D., Assistant Professor, Therapeutic Radiology, Yale University School of Medicine

Clinical Evaluation of Blood-Based Biomarkers

Shidong Jia, Ph.D., Scientist, Oncology Biomarker Development, Genentech, Inc.

Use of Non-Invasive Tumor Sequencing Assay on Patients with Advanced Cancers and its Clinical Utility

AmirAli Talasaz, Ph.D., President & CTO, Guardant Health, Inc.

Clinical Utility of a Novel Approach of Digital Sequencing Assessment of Circulating Cell-Free DNA in Melanoma Patients

Dave Hoon, Ph.D., Director & Professor, Molecular Oncology, John Wayne Cancer Institute


NEW APPLICATIONS IN CIRCULATING RNA

Challenges in Measuring Circulating Nucleic Acids

Kai Wang, Ph.D., Principal Scientist, Institute for Systems Biology

Isolation of Circulating MicroRNAs from Microvesicles Found in Human Plasma

Pamela B. Cassidy, Ph.D., Research Associate Professor, Dermatology, Oregon Health and Science University


TECHNOLOGY TO CAPTURE AND CHARACTERIZE

Detection and Quantitative Monitoring of ctDNA Mutation Status in Cancer Patients

Mark Erlander, Ph.D., CSO, Trovagene Inc.

Measuring Circulating Tumor DNA in Plasma by Picoliter Droplet-Based PCR for Colorectal Cancer Patient Follow-Up

Valerie Taly, Ph.D., Group Leader, Translational Research and Microfluidics, University Paris Descartes; and co-authors: Garlan F., Didelot A., Perkins G., Rice N., Zaanan A., Laurent-Puig P.

Next-Generation Sequencing of Methylated-Free Circulating DNA to Develop a Blood-Based Biomarker for Ovarian Cancer

Kristina Warton, Ph.D., Senior Research Officer, Cancer, University of New South Wales and Kinghorn Cancer Center, Garvan Institute



For more details on the conference, please contact:
Samantha Lewis
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5461
E: slewis@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

Joseph Vacca (Companies L-Z)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com 

 

  2015 Plenary Sessions 

2015 MMTC Prelim Agenda 

Premier Sponsors:

Elsevier 


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Singulex 

Thomson Reuters-Large 


Local Partners:

BayBio 


biocube 


Cabs 

City of SSF